Rollins Stanley

There may be new hope for many cancer patients, their caregivers and family members.

That's because America's research-based pharmaceutical businesses are to-day creating not exactly 400 new medications to take care of cancer, based on a review of continuing research performed by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Many of the medicines now in development represent potential break-through cancer solutions, although some contain possible new uses for existing medicines.

The medicines in devel-opment are all either in clinical trials or under evaluation by the Food and Drug Administration. They include:

• 62 for lung cancer, the leading cause of cancer death in the United States;

• 4-9 for breast cancer, that will be likely to strike more than 200,000 American women this year;

• 5-0 for prostate cancer, which will be likely to kill a lot more than 30,000 American men this year; and

• 35 for colorectal cancer, the next most common cancer in both men and women in the U.S.

Other possible treatments target elimination cancer, pancreatic cancer, head cancer, skin cancer, ovarian cancer and others. Identify more about wwe class action lawsuit by visiting our lofty article directory. To read more, please check-out: wwe concussion lawsuit. Additionally, companies will work on new treatments to enhance the standard of life for individuals undergoing cancer treatment.

'Anyone fighting cancer or anyone who has crushed it knows the significance of these medicines and this research,' mentioned Billy Tauzin, PhRMA president and CEO who is also a cancer survivor. 'Sometimes, the hope that among these new treatments will work for you is what keeps you fighting the condition.'

Recent cancer research efforts have led to several new treatments. As an example, a medicine to treat metastatic colorectal cancer may be the first treatment accepted that prevents the synthesis of new blood vessels that provide tumors with oxygen and nutrients. There's also a medicine for treating nonsmall-cell lung cancer that inhibits the growth and formation of cancer cells.